[
    [
        {
            "time": "",
            "original_text": "西南证券维持华大基因持有评级，2021年中报点评：新冠业务影响表观增速，常规业务恢复稳健增长",
            "features": {
                "keywords": [
                    "华大基因",
                    "持有评级",
                    "2021年中报",
                    "新冠业务",
                    "表观增速",
                    "常规业务",
                    "稳健增长"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "西南证券维持华大基因持有评级，2021年中报点评：新冠业务影响表观增速，常规业务恢复稳健增长",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 3,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        }
    ]
]